.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
Express Scripts
QuintilesIMS
Fuji
Mallinckrodt
Colorcon
Julphar
Novartis
Merck

Generated: September 26, 2017

DrugPatentWatch Database Preview

MOVANTIK Drug Profile

« Back to Dashboard

What is the patent landscape for Movantik, and when can generic versions of Movantik launch?

Movantik is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has ninety patent family members in thirty-seven countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

Summary for Tradename: MOVANTIK

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Clinical Trials: see list8
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MOVANTIK at DailyMed

Pharmacology for Tradename: MOVANTIK

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MOVANTIK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,349,307Polymer conjugates of opioid antagonists► Subscribe
8,034,825Chemically modified small molecules► Subscribe
2,015,197,470► Subscribe
9,388,104Chemically modified small molecules► Subscribe
9,149,539Crystalline naloxol-PEG conjugate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MOVANTIK

Country Document Number Estimated Expiration
Denmark2939696► Subscribe
Cuba20130047► Subscribe
Eurasian Patent Organization200601167► Subscribe
Japan2007514761► Subscribe
Luxembourg92702► Subscribe
Serbia54488► Subscribe
Israel225308► Subscribe
Canada2812649► Subscribe
SloveniaEP2939696► Subscribe
South Korea100974842► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MOVANTIK

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2015Austria► SubscribePRODUCT NAME: NALOXEGOL, GEGEBENENFALLS IN FORM EINES THERAPEUTISCH VERTRAEGLICHEN SALZES, INSBESONDERE ALS OXALAT; REGISTRATION NO/DATE: EU/1/14/962 20141208
2015019,C1694363Lithuania► SubscribePRODUCT NAME: NALOKSEGOLAS, KONKRECIAI NALOKSEGOLO OKSALATO DRUSKA; REGISTRATION NO/DATE: EU/1/14/962 20141208
C0037France► SubscribePRODUCT NAME: NALOXEGOL OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'OXALATE DE NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141210
90027-7Sweden► SubscribePRODUCT NAME: NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141210
2015000037Germany► SubscribePRODUCT NAME: NALOXEGOL ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/962 20141208
2015 00028Denmark► SubscribePRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141210
15/024Ireland► SubscribePRODUCT NAME: NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE OXALATE SALT OF THE ALPHA-EPIMER OF NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141208
2015 00028Denmark► SubscribePRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141208
702Luxembourg► SubscribePRODUCT NAME: NALOXEGOL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (MOVENTIG); FIRST REGISTRATION: 20141210
4 5008-2015Slovakia► SubscribePRODUCT NAME: OXALAT NALOXEGOLU; REGISTRATION NO/DATE: EU/1/14/962 20141210
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Moodys
Express Scripts
Cantor Fitzgerald
Baxter
Argus Health
Covington
Fish and Richardson
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot